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Summary
Background: Fatty liver disease (FLD) is the most common cause of liver dysfunction 
in developed countries. There is great interest in developing clinically valid and mini-
mally invasive biomarkers to enhance early diagnosis of FLD.
Aim: To investigate the potential of circulatory microRNAs (miRNAs) as biomarkers 
of FLD at the population level.
Methods: Plasma levels of 2083 miRNAs were measured by RNA sequencing in 1999 
participants from the prospective population-based Rotterdam Study cohort. The 
Hounsfield Unit (HU) attenuation of liver was measured using non-enhanced com-
puted tomography (CT) scan. Logistic and linear regression models adjusting for po-
tential confounders were used to examine the association of circulatory miRNAs with 
liver enzymes (n = 1991) and CT-based FLD (n = 954). Moreover, the association of 
miRNAs with hepatic steatosis and liver fibrosis was assessed longitudinally in indi-
viduals who underwent abdominal ultrasound (n = 1211) and transient elastography 
(n = 777) after a median follow-up of >6 years.
Results: Cross-sectional analysis showed 61 miRNAs significantly associated with 
serum gamma-glutamyl transferase and/or alkaline phosphatase levels (Bonferroni-
corrected P < 8.46 × 10−5). Moreover, 17 miRNAs were significantly associated 
with CT-based FLD (P < 8.46 × 10−5); 14 were among miRNAs associated with liver 
enzymes. Longitudinal analysis showed that 4 of these 14 miRNAs (miR-193a-5p, 
miR-122-5p, miR-378d and miR-187-3p) were significantly associated with hepatic 
steatosis (P < 3.57 × 10−3) and three (miR-193a-5p, miR-122-5p and miR-193b-3p) 
were nominally associated with liver fibrosis (P < 0.05). Nine of the 14 identified 
miRNAs were involved in pathways underlying liver diseases.
Conclusions: Plasma levels of several miRNAs can be used as biomarkers of FLD, lay-
ing the groundwork for future clinical applications.
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1  | INTRODUC TION
Fatty liver disease (FLD), is the most common cause of liver dysfunc-
tion in developed countries, that is also increasing in developing coun-
tries,1 is defined as an excess accumulation of fat in hepatocytes.2 
Specifically, non-alcoholic fatty liver disease (NAFLD) is character-
ised by fat accumulation in hepatocytes not due to excess alcohol 
consumption.3 The disorder covers a broad spectrum of underlying 
conditions, ranging from simple fatty liver to inflammation, which can 
progress to fibrosis, cirrhosis and even liver cancer.4 FLD is strongly 
associated with obesity, hypertension, dyslipidaemia and insulin resis-
tance, regarded as hepatic manifestation of the metabolic syndrome.5 
Currently, liver biopsy is the gold standard for diagnosing and stag-
ing of FLD, but its application is limited by the invasive nature, risk 
of complications and high cost.6 Various imaging modalities, such 
as computed tomography (CT) scan and ultrasound, have also been 
used for detecting the presence or quantifying the severity of liver fat 
noninvasively.7 However, the limited diagnostic accuracy of detecting 
mild degree hepatic steatosis with CT and ultrasound is an issue that 
should be taken into consideration.7 Transient elastography is non-in-
vasive technique that uses both ultrasound and low-frequency elastic 
waves to qualify liver fibrosis. However, recent research suggests that 
steatosis may influence its diagnostic performance.8 Controlled at-
tenuation parameter (CAP) is an ultrasound-based diagnostic method 
and added to transient elastography enables simultaneous assess-
ment of steatosis and fibrosis,9 but the clinical application of CAP is 
limited by influences of covariates.10 Therefore, the development of 
clinically valid and minimally invasive methods is required to enhance 
early diagnosis of FLD.
MicroRNAs (miRNAs) are small non-coding RNA molecules of 
20-25 nucleotides in length that regulate gene expression at the 
post-transcriptional level.11 Recently, the interest in miRNAs has in-
creased tremendously because they offer new insights into disease 
mechanisms and have a great potential to be used in the clinic as 
diagnostic biomarkers and/or even therapeutic targets.12,13 In line 
with this, numerous studies have reported increased levels of circu-
lating miR-122 in liver diseases with different aetiologies and sug-
gested this miRNA as a potential biomarker and target of therapy 
in liver dysfunction.14,15 Although extensive research has explored 
the role of miRNAs in the pathophysiology of liver diseases, little is 
known about the potential of circulatory miRNAs as FLD biomarker 
in the population level. Moreover, the available studies have mainly 
used qPCR-based methods and limited to small number of miRNAs 
and sample sizes.16,17
The aim of this study was to systematically investigate the as-
sociation of circulating miRNAs in plasma with FLD in a popula-
tion-based setting. To achieve this aim, we conducted regression 
models to identify miRNAs that are associated with FLD and liver en-
zymes at the baseline in the Rotterdam Study (RS) cohort. Moreover, 
we performed subsequent analyses to check whether the identified 
miRNAs are linked to the risk of hepatic steatosis or liver fibrosis 
after follow-up and are involved in the known pathways underlying 
liver diseases.
2  | MATERIAL S AND METHODS
2.1 | Study population
This study was embedded within the framework of the RS, a pro-
spective cohort study of individuals aged ≥45 years living in the 
Ommoord district of Rotterdam, the Netherlands. The objectives 
and design of the RS have been described in detail elsewhere.18 In 
1989, the first cohort of study participants (RS-I) comprised 7983 
persons aged 55 years or over. In 2000, the second cohort (RS-II) 
was extended to include an additional 3011 participants who moved 
into the study district or had become 55 years of age. A further ex-
tension of the RS cohort (RS-III) formed in 2006 and include 3932 
participants living in the research area and aged 45 years and older. 
Follow-up examinations were scheduled periodically, approximately 
every 3-5 years. All participants in the study provided written inform 
consent to participate and to obtain information from their treating 
physicians.
For this study, we used the expression profiles of circulating 
miRNA in plasma, collected between 2002 and 2005, from a random 
subset (n = 1000) of the fourth visit of the first cohort (RS-I-4) and 
a random subset (n = 999) of the second visit of the second cohort 
(RS-II-2). Among them, 1991 participants had serum gamma-glu-
tamyl transferase (GGT) and Alkaline phosphatase (ALP) levels avail-
able at baseline that were included to investigate the association of 
miRNAs with liver enzymes. Moreover, 954 participants who under-
went CT-scan from June 2003 to February 2006 were included for 
investigating the associations of miRNAs with FLD in a cross-sec-
tional setting (Figure 1).
For the longitudinal analysis, 1999 participants at the baseline 
were followed up >6 years, until the fifth visit of the first cohort 
(RS-I-5) and the third visit of the second cohort (RS-II-3). Among 
these, 1211 participants who underwent abdominal ultrasound 
between January 2009 and June 2014 were included to investi-
gate the association of miRNAs with hepatic steatosis (424 cases). 
Of these, 1147 participants were included to investigate the as-
sociation of miRNAs with NAFLD (321 cases) and alcoholic FLD 
(76 cases). Moreover, out of the 1999 individuals, 777 participants 
who underwent transient elastography were included to inves-
tigate the association of miRNAs with liver fibrosis (33 cases). A 
more detailed flow chart for the selection of study participants is 
shown in Figure 1.
2.2 | MiRNA expression profiling
Plasma levels of cell-free miRNAs were determined using the HTG 
EdgeSeq miRNA Whole Transcriptome Assay (WTA), which meas-
ures the expression of 2083 human mature miRNAs. The WTA 
characterises miRNA expression patterns, and measures the ex-
pression of 13 housekeeping genes, that allows flexibility in data 
normalisation and analysis. Plasma samples, for two re-measure-
ments that generally is sufficient to obtain a valid result for all 
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samples, were sent to HTG Molecular Diagnostics for sequenc-
ing. Each sample was tagged individually with molecular bar-
codes, tagged samples were pooled and sequenced on an Illumina 
NextSeq 500 sequencer (Illumina). Quantification of miRNA ex-
pression was based on counts per million (CPM). The log2 trans-
formation of CPM was used as standardisation and adjustment for 
total reads within each sample. The miRNAs with log2 CPM < 1.0 
were considered as not expressed in the samples. Of the 2083 
miRNAs, 591 miRNAs were expressed at good levels in plasma. 
These 591 well-expressed miRNAs are those with >50% values 
above Lower Limit of Quantification (LLOQ). The LLOQ level is 
based on a monotonic decreasing spline curve fit between the 
means and standard deviations of all miRNAs.
2.3 | Assessment of liver fat with CT scan
As part of a larger project on the assessment of vascular calcifica-
tion, ECG-gated, cardiac, non-enhanced CT scanning on a 16-slice 
(n = 251) or 64-slice (n = 703) multi-detector CT scanner (Somatom 
Sensation 16 or 64, Siemens). Imaging parameters of the scans are 
described in detail elsewhere.19
Using these cardiac scans, we evaluated the liver density (at-
tenuation) using a standardised procedure. First, we placed three 
circular regions of interest (ROIs) in the liver and calculated the 
mean liver attenuation (LA) within these regions.20 These ROIs are 
delineated throughout the imaged liver tissue (including both the 
left and right liver lobes) are carefully chosen to include only liver 
tissue, and avoiding the large blood vessels, cysts or focal lesions. 
Next, we calculated the mean Hounsfield unit (HU) value from 
these three measurements as a marker of total amount of liver 
fat, which is a reliable proxy for the mean LA value of the whole 
liver.20 All measurements were done using Philips iSite Enterprise 
software (Royal Philips Electronics NV 2006) and described in de-
tail elsewhere.21
The CT diagnosis of liver fat is made by measuring mean LA in 
HU or the difference between the liver and spleen.20 As the amount 
of liver fat increases, the measured LA decreases, that means low LA 
was equal to high risk of fatty liver. However, in the present study 
FLD was defined as mean LA <40 HU.22
F I G U R E  1   An overview of the study to identify circulatory miRNAs associated with FLD. Cross-sectional studies at baseline were 
performed in participants from RS-I-4 and RS-II-2 with liver enzymes and CT-scan data available. Longitudinal studies were performed in 
participants from RS-I-5 and RS-II-3 who underwent abdominal ultrasound or transient elastography. Abbreviations: AFLD, alcoholic fatty 
liver disease; ALP, Alkaline phosphatase; CT, computed tomography; FLD, fatty liver disease; GGT, gamma-glutamyl transferase; LSM, liver 
stiffness measurement.; miRNAs, microRNAs; NAFLD, non-alcoholic fatty liver disease; RS, Rotterdam Study; RS-I-4, the fourth visit of 
the first cohort; RS-I-5, the fifth visit of the first cohort; RS-II-2, the second visit of the second cohort; RS-II-3, the third visit of the second 
cohort
miRNA expression profiling data from participants in RS-I-4 (n = 1000) and RS-II-2 (n = 999) 
8 excluded due to no GGT or ALP data 
1,991 participants included in the cross-sectional study investigate the 
association of miRNAs with GGT and ALP 
Excluded (n = 1,045) 
- No CT-scan 
measurement (n = 1,037) 
- Insufficient amount of 
imaged liver (n = 8) 
788 excluded due to no 
abdominal ultrasound data 
1,211 participants in RS-I-5 and RS-II-3 
included in the longitudinal study between 
miRNAs and hepatic steatosis 
64 excluded due to viral hepatitis 
or medication use associated 
with hepatic steatosis or 
unknown status 
Excluded (n = 1,222): 
- With pacemaker (n = 6); 
- LSM failure (n = 113); 
- Unreliable LSM (n = 35); 
- No FibroScan data (n = 1,068) 
954 participants included in the cross-
sectional study between miRNAs and FLD 
1,147 participants in RS-I-5 and RS-II-3 
included in the longitudinal study on 
miRNAs with NAFLD and AFLD 
777 participants in RS-I-5 and RS-II-3 
included in the longitudinal study between 
miRNAs and liver fibrosis
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2.4 | Assessment of hepatic steatosis and 
liver fibrosis
Hepatic steatosis was assessed by using abdominal ultrasound, 
which was carried out by a certified and skilled technician (Pavel 
Taimr) on Hitachi HI VISION 900.23 Images were stored digitally and 
re-assessed by a single hepatologist with more than 10 years of ex-
perience in ultrasonography. Diagnosis of steatosis was determined 
dichotomously as presence of a hyperechogenic liver parenchyma 
according to the protocol by Hamaguchi et al24
Moreover, liver fibrosis was assessed using transient elastog-
raphy (FibroScan®, EchoSens). Applied implementation of this ex-
amination has been described in detail previously.25 Liver stiffness 
measurement (LSM) was performed by a single certified and experi-
enced operator, who obtained 10 serial measurements using either 
the M or XL-probe dependent on the thickness of the subcutaneous 
fat layer.23 Moreover, LSM interquartile range/median LSM > 0.3 ki-
lopascals (kPa) and LSM ≥ 7.1 kPa were regarded as poorly reliable.26 
In the present study, LSM ≥ 9.0 kPa was used as a cut-off suggesting 
clinically relevant liver fibrosis.8
2.5 | Assessment of covariates and liver enzymes
Information on smoking behaviour, medication use and blood sampling, 
was obtained during home interviews.18 Height and weight were meas-
ured, and the body mass index (BMI) [(weight in kg)/(height in m)2] was 
calculated. Waist circumferences were measured at the level midway 
between the lower rib margin and the iliac crest with the participant 
in a standing position. Smoking status was categorised into never, cur-
rent or former. These data were further classified to two groups in-
cluding never-smokers and ever-smokers (current and former smokers 
combined). Alcohol consumption was assessed in grams of ethanol per 
day and was classified (yes/no). Excessive alcohol consumption was de-
fined as alcohol intake >30 g/day for men and >20 g/day for women.23 
Hypertension was defined as a systolic blood pressure (BP) ≥140 mm 
Hg or a diastolic BP ≥ 90 mm Hg or the use of BP-lowering drugs pre-
scribed for hypertension.27 Diabetes mellitus was defined according 
to recent WHO guidelines28 as fasting blood glucose ≥7.0 mmol/L or 
non-fasting blood glucose between ≥11.1 mmol/L or the use of antidia-
betic medication. From the blood samples, concentrations high-den-
sity lipoprotein (HDL) cholesterol were determined using enzymatic 
procedures.29 Serum GGT and ALP levels were determined within 
2 weeks using a Merck Diagnostica kit on an Elan Autoanalyzer (Merc). 
According to local cut-offs, elevation of GGT was defined as >34 U/L 
for women and >49 U/L for men, and elevation of ALP was defined as 
>97 U/L for women and >114 U/L for men.30
2.6 | Statistical analysis
Continuous variables are reported as mean ± standard deviation (SD) 
unless stated otherwise and categorical variables were presented 
as sample sizes and percentages. To obtain a normal distribution, 
skewed variables (serum HDL cholesterol, GGT and ALP) were log 
transformed. In addition, the amount of liver fat (A) had a left skewed 
and we used exponential transformed values (B) using the formula 
[B = A3.5/10 000].21
Multivariable linear and logistic regression models were used 
to investigate the association between miRNA levels and CT-based 
FLD (with the HU continues and dichotomous data). The multivari-
able linear regression models were used to check the association 
of miRNA levels with serum GGT and ALP levels. Beta, standard 
error (SE), P value were reported. The Bonferroni-corrected p 
value threshold was calculated based on the number of tested 
miRNAs (0.05/591 = 8.46 × 10−5). In basic model (model 1), we ad-
justed the analysis for age and sex. The multivariable model (model 
2), was additionally adjusted for waist circumference, ever smok-
ing, alcohol consumption, hypertension, diabetes mellitus and 
serum HDL cholesterol. Because the missing values were likely to 
be missing at random and for avoidance of loss in efficiency, miss-
ing values on covariates (ranging from 0.1% to 1.7%) were imputed 
using a multiple imputation technique (N = 5 imputations). All 
analyses were done using SPSS statistical software (SPSS, version 
25; IBM Corp) and R software version 3.5.2 (The R Foundation for 
Statistical Computing).
Sensitivity analyses were performed by adjusting for more 
variables. Model 3 was built by adding GGT and ALP to model 2. 
In model 4, we further adjusted for potential intermediator factors 
including in the model 2, use of lipid-lowering medication, use of bile 
and liver medications. In model 5, we adjusted for all potential inter-
mediator factors (including model 2, GGT, ALP, use of lipid-lowering 
medication, use of bile and liver medications).
Furthermore, multivariable logistic regression models were used 
to investigate longitudinally the association of the plasma levels of 
the identified miRNAs with prevalence of hepatic steatosis and liver 
fibrosis after a median follow-up of 6.4 years [interquartile range 
(IQR): 5.9-7.0 years]. The Bonferroni correction was used to set the 
significance threshold.
Two databases, the Human miRNA tissue atlas (https://ccb-
web.cs.uni-saarl and.de/tissu eatlas)31 and Human miRNA expres-
sion profiles (https://guanf iles.dcmb.med.umich.edu/mirmi ne/
index.html), were used to check whether the identified miRNAs 
are expressed in the liver. We also searched the literature32−35 and 
several web tools (eg miR2Disease and GWAS catalogue) to see 
whether the identified miRNAs are associated with liver function 
and diseases.
3  | RESULTS
At baseline, 954 participants who had miRNA expression data and 
CT-based liver fat measurement were included to test the associa-
tion of miRNAs and FLD. The mean age of the study population was 
68.8 ± 6.7 years, and 46.6% were male. The mean LA in the popula-
tion was 61.6 HU (IQR: 55.4-65.6 HU). Among the study participants, 
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14.8% were diagnosed with cancer, but none of them was diagnosed 
with liver cancer. At follow-up, 1211 participants who had under-
went abdominal ultrasound were included to test the association of 
miRNAs and hepatic steatosis. The mean age of the study population 
was 76.3 ± 6.5 years, and 42.4% were male. Lifestyle, clinical and 
biochemical characteristics of all study participants are presented 
in Table 1. Comparison of characteristics between healthy controls 
and FLD patients based on CT-scan and ultrasound data (in baseline 
and follow-up study) are shown in Table S1. The participants with 
FLD have significantly higher BMI, waist circumference and alcohol 
consumption than healthy controls. In addition, compare to healthy 
controls, individuals with FLD have significantly lower serum HDL 
cholesterol.
In the linear regression analysis with liver enzymes, 37 miRNAs 
were significantly associated with serum GGT levels and 29 miRNAs 
with serum ALP levels, at the Bonferroni-corrected P < 8.46 × 10−5 
(0.05/591 well-expressed miRNAs) (Tables S2 and S3 respectively). 
Volcano plot showing differently expressed miRNAs in relation to 
GGT and ALP levels is depicted in Figure 2A,B.
Using a linear regression analysis of the continuous HU values, 
in the multivariable model 2, we found 15 miRNAs to be signifi-
cantly associated at Bonferroni-corrected P < 8.46 × 10−5 (Table S4). 
Volcano plot showing differently expressed miRNAs in relation to 
the continuous HU values is depicted in Figure 2C. In addition, in 
a logistic regression model testing the association of miRNA lev-
els with the dichotomous HU values assessing FLD (mean LA ≤ or 
>40), six miRNAs were significantly associated (P < 8.46 × 10−5) 
(Figure 3). In model 3, further adjusting for GGT and ALP changed 
slightly the associations and with less miRNAs significant associ-
ated, but 2 of the 17 and 6 of 17 miRNAs remained significant using 
dichotomous and continuous Hounsfield Unit values respectively 
(P < 8.46 × 10−5) (Tables S5 and S6). Additional adjustment for use of 
lipid-lowering medication, use of bile and liver medications (model 4) 
did not change the observed associations between miRNAs and FLD 
(Tables S5 and S6). In model 5, we added GGT, ALP, use of serum lipid 
reducing agents, use of bile and liver medications to model 2, the 
associations of miRNAs with FLD were similar to model 3, the same 
miRNAs remained significant (Tables S5 and S6).
Collectively, our cross-sectional studies with the baseline data 
revealed 61 unique miRNAs associated with liver enzymes (GGT 
and/or ALP) and 17 unique miRNAs associated with CT-based 
FLD (continuous or dichotomous HU values). Of these, 14 miRNAs 
were common in both lists that were selected for further analyses 
(Table 2).
The longitudinal analysis was performed for the 14 miRNAs by 
using ultrasound and FibroScan data. Using a logistic regression 
in the multivariable model 2, we found significant association be-
tween 4 of the 14 miRNAs (miR-193a-5p, miR-122-5p, miR-378d 
and miR-187-3p) with hepatic steatosis at Bonferroni-corrected 
P < 3.57 × 10−3 (0.05/14 miRNAs) (Table 3). Moreover, we found 
significant association of miR-122-5p and miR-187-3p with NAFLD 
(P < 3.57 × 10−3), and miR-3937 was nominally (P < 0.05) associ-
ated with alcoholic FLD (Table S7). Using FibroScan data and in a 
multivariable logistic regression model, we also found miR-193a-5p 
(P = 5.58 × 10−3, β = 1.11), miR-122-5p (P = 0.0147, β = 0.45) and 
miR-193b-3p (P = 0.0102, β = 1.19) to be nominally associated with 
liver fibrosis (Table 3).
Additionally, we searched the Human miRNA tissue atlas and the 
miRmine database to see whether the 14 miRNAs associated with 
FLD in plasma are expressed in the liver that are shown in Table S8. 
Among them, miR-122-5p is a specifically expressed miRNA with the 
tissue specificity index (TSI) of 0.97 and highly expressed in the liver. 
Then, we sought to find whether the 14 identified miRNAs are re-
ported in previous studies to be associated with liver function or/
and diseases. A summary of evidence for associations between nine 
of these miRNAs and liver diseases are shown in Table S9. Finally, we 
TA B L E  1   Characteristics of the study population
Characteristic
Baseline 
(n = 954) with 
CT-scan data
Follow-up 
(n = 1211) with 
ultrasound 
data
Age, years 68.8 ± 6.7 76.3 ± 6.5
Male, n (%) 445 (46.6) 513 (42.4)
Body mass index (kg/m2) 27.9 ± 4.0 27.5 ± 4.1
Waist circumference (cm) 94.4 ± 11.7 93.2 ± 12.0
Hypertension, n (%) 709 (74.3) 1047 (86.5)
Blood pressure-lowering 
medication, n (%)
385 (40.4) 644 (53.2)
Smoking status, n (%)
Ever 677 (71.0) 791 (65.3)
Current 130 (13.6) 116 (9.6)
Former 547 (57.4) 675 (55.7)
Diabetes mellitus, n (%) 123 (12.9) 156 (12.9)
Use of lipid-lowering 
medication, n (%)
246 (25.8) 372 (30.7)
Alcohol intake (g/day) 8.6 (1.4-20.0) 8.6 (1.6-8.6)
Mean liver attenuation (HU) 61.6 
(55.4-65.6)
−
Serum HDL cholesterol 
(mmol/L)
1.4 (1.2-1.7) 1.4 (1.2-1.7)








Cancer, n (%) 141 (14.8) −
Liver cancer, n (%) 0 (0) −
Fatty liver, n (%) 47 (4.93) 424 (35)
Note: The table shows characteristics of 954 participants with CT-
scan data at baseline and 1211 participants with ultrasound data at 
follow-up. Values are represented as mean (±standard deviation), 
sample sizes (%), or median (inter-quartile range) for characteristics with 
skewed distributions.
Abbreviations: ALP, Alkaline phosphatase; BP, blood pressure; GGT, 
Gamma-glutamyl transferase; HDL, high-density lipoprotein; HU, 
Hounsfield unit.
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extracted SNPs annotated to the 16 identified miRNAs and checked 
their associations with FLD and liver enzymes using summary statis-
tics data from pervious GWAS.34,35 There were 63 SNPs related to 
miR-193a-5p, miR-378d and miR-193b-3p, none of them showed sig-
nificant association after correcting the P value for multiple testing 
based on the number of tested SNPs.
4  | DISCUSSION
In this study, we investigated the association between circulating 
miRNAs and liver enzymes in a population-based setting and found 
61 unique miRNAs to be associated with serum GGT or ALP levels. 
Moreover, we found plasma levels of 17 miRNAs to be associated 
with CT-based FLD, 14 of these were also associated with the liver 
enzymes. Higher plasma levels of three and lower plasma level of 1 
of the 14 miRNAs were significantly associated with hepatic stea-
tosis after >6 years follow-up. These findings suggest that plasma 
levels of miRNAs can be considered as potential biomarkers of FLD 
and hepatic steatosis in the general population.
Several studies have demonstrated the potential of miRNAs to 
be used as biomarkers for liver diseases.36−38 However, previous 
studies have conducted for subset of miRNAs, using qPCR-based 
methods, or on the modest sample sizes. While our study is em-
bedded within the RS with much larger sample size, based on 
RNA-sequencing method, conducted genome-wide profiling of 
almost all important cell-free miRNAs, and adjusted for a broad 
range of potential confounders, such as waist circumference, 
smoking status, alcohol consumption, hypertension and diabetes 
mellitus, which have been overlooked in most of previous stud-
ies.36,39 Such a large-scale population-based study with long-term 
follow-up data provided a more statistical power to detect multiple 
significant associations. Compared to microarray or qPCR-based 
profiling techniques, the cell-free RNA-seq analysis can provide 
higher sensitivity to measure miRNAs expression levels over a 
wide dynamic range and with ability to identify novel miRNAs.40 
Additionally, due to the high stability of cell-free miRNAs in body 
fluids and accessibility of plasma compared with the target tissue, 
the identified miRNAs can be considered as potential easy-to-use 
biomarkers in clinical routine.41
F I G U R E  2   Volcano plots showing correlation between plasma levels of miRNAs and GGT (A), ALP (B), and continuous Hounsfield Unit 
values (C). The red dots indicate miRNAs significantly associated at Bonferroni-corrected P < 8.46 × 10−5. The grey dots indicate miRNAs 
with no significant association. The name of miRNAs that were significantly associated with liver enzymes and the continuous Hounsfield 
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Previous studies on human or mouse model have demonstrated 
particularly miR-122-5p as potential biomarkers and therapeutic tar-
get for liver diseases.39,42,43 In line with previous studies, we found 
that the higher plasma miR-122-5p level is significantly associated 
with FLD and liver enzymes also in a population-based setting. In 
addition to the well-established liver-associated miR-122, we found 
evidence in previous studies for eight of the other identified miR-
NAs in our study to be associated with liver diseases, indicating the 
importance of these miRNAs in pathways underlying liver function 
and diseases. In particular, the expression of miR-193a-5p, which is 
one of our top miRNAs associated with FLD and hepatic steatosis, is 
reported to be upregulated in HCC tissues,44 whereas miR-193a-5p 
can distinguish HCC from other non-HCC individuals43 and inhibited 
HCC development through targeting SPOCK1.45 Similarly, miR-422a 
was related to NAFLD,46 miR-378d47 miR-187-3p,48 miR-6809-5p49 
and miR-448450 were associated with HCC. Moreover, miR-193b-3p 
which were significantly associated with FLD and nominally associ-
ated with liver fibrosis in our study, have been verified previously to 
be involved in the pathogenesis of liver fibrosis in vitro.51 Finally, the 
members of miR-378 family, in particular miR-378a-3p that has been 
also proposed to have a therapeutic potential for liver fibrosis.52
Our results showed a minimal of the use of serum lipid reducing 
agents, use of bile and liver medications on the observed associations 
between miRNAs and FLD. We observed slightly change in the as-
sociations between miRNAs and FLD by adding GGT and ALP to the 
model. This difference may indicate that liver enzymes have more 
stronger links to FLD compared to medication use. Also, we did not 
find significant association between SNPs related to the identified 
miRNAs and FLD in the summary statistics from previous GWAS, but 
we need to take into consideration the sample sizes of available GWAS 
of liver diseases. To date, the GWAS on liver diseases is mainly from 
two studies,34,35 Nakamura et al conducted a study to identify sus-
ceptibility loci for primary biliary cirrhosis, a GWAS in 963 Japanese 
individuals and in a subsequent replication study including 1402 other 
Japanese individuals. The sample sizes of this study are limited and 
the analysis conducted in Asia population, while our study was con-
ducted in European population, and miRNAs expression might ex-
hibits population differences.53 In addition, Namjou et al conducted 
a GWAS using both adult and paediatric participants (1106 NAFLD 
cases and 8571 controls) from electronic medical records to iden-
tify genetic contributions to NAFLD. As the cohorts in that GWAS 
study represent many geographic area in US, other ancestry groups 
F I G U R E  3   Comparison between expression levels of the top 10 miRNAs in patients with fatty liver disease and healthy controls. Of 
these, 6 miRNAs (miR-193a-5p, miR-378a-3p, miR-422a, miR-378d, miR-320d and miR-378e) were significantly associated with fatty liver 
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TA B L E  2   Circulatory miRNAs significantly associated with CT-scan-based fatty liver disease and serum liver enzymes
miRNA ID
CT-based FLD Liver Enzymes
Dichotomous HU values Continues HU values GGT ALP
Beta P value Beta P value Beta P value Beta P value
miR-193a-5p 1.86 2.02 × 10−10a −35.88 4.26 × 10−12a 0.14 6.15 × 10−29a 0.001 7.99 × 10−01
miR-4484 0.71 8.33 × 10−4 −20.04 6.02 × 10−08a 0.03 4.02 × 10−05a 0.01 3.68 × 10−04
miR-1306-5p −0.60 3.15 × 10−01 55.59 1.21 × 10−07a −0.09 6.45 × 10−05a −0.02 1.12 × 10−01
miR-378a-3p 2.36 1.90 × 10−07 −34.61 1.95 × 10−06a 0.09 8.45 × 10−08a −0.01 3.98 × 10−01
miR-6803-5p 0.70 2.68 × 10−02 −27.96 2.01 × 10−07a 0.05 6.31 × 10−05a 0.01 1.03 × 10−02
miR-6870-3p −0.59 1.60 × 10−02 25.79 3.87 × 10−07a −0.06 9.04 × 10−08a −0.02 8.00 × 10−05a
miR-3937 −0.54 1.83 × 10−03 15.02 6.59 × 10−07a −0.03 1.90 × 10−06a −0.01 3.84 × 10−04
miR-122-5p 0.54 1.72 × 10−04 −12.74 8.05 × 10−06a 0.14 2.39 × 10−116a 0.01 4.73 × 10−04
miR-422a 2.01 9.87 × 10−06a −25.07 6.09 × 10−05a 0.06 9.71 × 10−06a 0.002 7.37 × 10−01
miR-378d 1.75 1.11 × 10−05a −26.00 5.87 × 10−06a 0.06 5.55 × 10−07a −0.004 4.92 × 10−01
miR-187-3p −1.31 2.52 × 10−02 48.67 1.33 × 10−05a −0.11 3.78 × 10−06a −0.03 1.80 × 10−02
miR-6809-5p −0.73 5.51 × 10−02 34.03 1.61 × 10−05a −0.08 1.45 × 10−06a −0.01 1.11 × 10−01
miR-193b-3p 1.01 2.70 × 10−03 −23.17 2.77 × 10−05 a 0.11 2.01 × 10−21a −0.001 7.85 × 10−01
miR-4713-3p −0.55 1.02 × 10−02 16.96 2.80 × 10−05a −0.03 8.53 × 10−04 -0.01 1.13 × 10−02
miR-320d 1.16 2.87 × 10−05a −14.30 4.54 × 10−03 0.02 1.72 × 10−01 0.004 4.10 × 10−01
miR-34b-3p −0.76 8.88 × 10−02 30.06 6.27 × 10−05a −0.06 1.79 × 10−04 −0.01 3.41 × 10−01
miR-378e 1.64 6.88 × 10−05a −21.54 6.86 × 10−04 0.06 3.13 × 10−05a −0.01 4.42 × 10−01
Note: Model 2: adjusted for age, sex, waist circumference, ever smoking, alcohol consumption, hypertension, diabetes mellitus and serum HDL 
cholesterol.
The table is sorted based on Bonferroni-corrected P value association of miRNAs with dichotomous or continues Hounsfield Unit values in model 2.
The Bonferroni-corrected significance threshold is P < 8.46 × 10−5 (0.05/591 miRNAs). The P values surpassing the significance threshold are “a”.
Abbreviations: ALP, Alkaline phosphatase; FLD, fatty liver disease; GGT, Gamma-glutamyl transferase; HU, Hounsfield Unit; miRNA, microRNA.
miRNA ID
Hepatic Steatosis Liver Fibrosis
Beta SE P value Beta SE P value
miR-193a-5p 0.54 0.16 2.02 × 10−10a 1.11 0.40 5.58 × 10−03b
miR-4484 0.21 0.10 4.65 × 10−02b 0.41 0.28 1.37 × 10−01
miR-1306-5p −0.33 0.28 2.36 × 10−01 −1.16 −0.73 1.14 × 10−01
miR-378a-3p 0.37 0.21 8.19 × 10−02 1.23 0.64 5.67 × 10−02
miR-6803-5p 0.13 0.15 3.79 × 10−01 0.70 0.41 8.42 × 10−02
miR-6870-3p −0.22 0.14 1.18 × 10−01 0.07 0.45 8.80 × 10−01
miR-3937 −0.13 0.09 1.44 × 10−01 −0.18 0.26 4.87 × 10−01
miR-122-5p 0.33 0.08 6.06 × 10−05a 0.45 0.18 1.47 × 10−02b
miR-422a 0.37 0.18 4.12 × 10−02b 0.96 0.54 7.61 × 10−02
miR-378d 0.54 0.17 1.65 × 10−03a 0.73 0.53 1.69 × 10−01
miR-187-3p −1.01 0.34 2.76 × 10−03a −0.42 0.98 6.68 × 10−01
miR-6809-5p −0.55 0.24 2.49 × 10−02b −0.66 −0.76 3.83 × 10−01
miR-193b-3p 0.22 0.15 1.42 × 10−01 1.19 0.46 1.02 × 10−02b
miR-378e 0.50 0.18 7.25 × 10−03b 0.94 0.60 1.14 × 10−01
Note: Model 2: adjusted for age, sex, waist circumference, ever smoking, alcohol consumption, 
hypertension, diabetes mellitus and serum HDL cholesterol. The table is sorted based on the 
association of 14 miRNAs with the continues Hounsfield Unit values in the cross-sectional study. 
The P values surpassing the Bonferroni-corrected threshold of P < 3.57 × 10−3 (0.05/14 miRNAs) 
are marked with “a” and nominal associations with P < 0.05 are marked with “b”. Abbreviations: 
miRNA, microRNA; SE, standard error.
TA B L E  3   Longitudinal study of the 14 
identified miRNAs with hepatic steatosis 
and liver fibrosis
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are under-represented in the electronic medical records. Thus, it is 
possible that future trans-ethnic GWAS with larger samples sizes find 
association between some of the identified miRNAs and FLD.
Our study has some limitations that should be considered. First, 
in the cross-sectional observational study the ability to assess cau-
sality or temporality is limited. We therefore assessed additionally 
the associations of the identified miRNAs as biomarkers for diagno-
sis hepatic steatosis after follow-up. Future studies are still needed 
to confirm our findings in longitudinal settings considering the in-
cidence date, longer follow-up time and in different age groups. 
Second, we defined the mean LA< 40 HU as FLD and found 47 cases 
out of 954 individuals (5%), which is lower than the excepted preva-
lence of FLD in the general population. A liver-to-spleen ratio < 1.0 
is comparable to using a mean LA cut-off ≤ 51 HU for diagnosis of 
mild liver fat.54 However, previous studies have demonstrated dif-
ferent cut-offs, mainly a cut-off value of 40 HU on non-enhanced 
CT as the most clinically indicator for moderate-to-severe steato-
sis.20,22 In our study, the cut-off value is 40 HU for FLD, it is rela-
tively strict than using the mean LA ≤ 51 HU, which increases the 
certainty of identifying participants with true FLD and also results in 
a lower prevalence. Therefore, we performed cross-sectional analy-
sis at baseline with the continuous HU values and liver enzymes as 
well. The majority (14 of 17) of the identified miRNAs with CT-scan 
data showed significant association with liver enzyme, indicating the 
robustness of our results. Yet, compare to the liver biopsy as the 
gold standard, but invasive method, to measure FLD, CT-based liver 
fat has limited diagnostic accuracy of detecting mild degree hepatic 
steatosis. Therefore, there might be some known or unknown causes 
for low density of the liver on CT scan. Also, there might be some 
inconsistency between CT-scans and ultrasound data for diagnosing 
FLD and hepatic steatosis. In an optimal setting, one should use the 
repeated measurement of liver fat by a similar diagnostic method for 
longitudinal analysis.
In conclusion, we found that plasma levels of several miRNAs 
were significantly associated with FLD that can be considered as 
plasma biomarkers of the disease in the population level. Future 
research need to be conducted even with more sample sizes and 
longer follow-up times in order to confirm the potential of the iden-
tified miRNAs as biomarkers for early diagnosis and progression 
of FLD and also to uncover underlying molecular mechanisms by 
which these miRNAs may control liver fat.
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